secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001082554-24-000027
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics Q1 2024 revenue up 34% to $677.7M; net income $306.6M
-------------------------------------------------------------------------

- Total revenues $677.7M (+34% YoY); Tyvaso product line grew 56% to $372.5M.
- Net income $306.6M ($6.17 diluted EPS) vs $240.9M ($4.86 EPS) in Q1 2023.
- Implemented $1B accelerated share repurchase with Citi; initial delivery of 3.275M shares.
- Tyvaso DPI sales $227.5M (+92% YoY); nebulized Tyvaso $145.0M (+21%).
- Revenue growth driven by increased patient utilization and Part D redesign tailwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255424000027/0001082554-24-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255424000027/uthr-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001082554-24-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer